VINC vs. FLGC, TRAW, TLPH, NERV, NRSN, TNXP, GLYC, VBIV, GLTO, and EDSA
Should you be buying Vincerx Pharma stock or one of its competitors? The main competitors of Vincerx Pharma include Flora Growth (FLGC), Traws Pharma (TRAW), Talphera (TLPH), Minerva Neurosciences (NERV), NeuroSense Therapeutics (NRSN), Tonix Pharmaceuticals (TNXP), GlycoMimetics (GLYC), VBI Vaccines (VBIV), Galecto (GLTO), and Edesa Biotech (EDSA). These companies are all part of the "pharmaceutical preparations" industry.
Vincerx Pharma (NASDAQ:VINC) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, community ranking, dividends, earnings, profitability and institutional ownership.
44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 36.0% of Flora Growth shares are held by institutional investors. 22.9% of Vincerx Pharma shares are held by insiders. Comparatively, 17.6% of Flora Growth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Flora Growth had 1 more articles in the media than Vincerx Pharma. MarketBeat recorded 10 mentions for Flora Growth and 9 mentions for Vincerx Pharma. Flora Growth's average media sentiment score of 0.32 beat Vincerx Pharma's score of -0.10 indicating that Flora Growth is being referred to more favorably in the news media.
Vincerx Pharma received 6 more outperform votes than Flora Growth when rated by MarketBeat users. Likewise, 64.52% of users gave Vincerx Pharma an outperform vote while only 60.87% of users gave Flora Growth an outperform vote.
Vincerx Pharma has a net margin of 0.00% compared to Flora Growth's net margin of -75.95%. Flora Growth's return on equity of -144.44% beat Vincerx Pharma's return on equity.
Vincerx Pharma has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, Flora Growth has a beta of 2, suggesting that its stock price is 100% more volatile than the S&P 500.
Vincerx Pharma has higher earnings, but lower revenue than Flora Growth.
Vincerx Pharma currently has a consensus target price of $5.00, suggesting a potential upside of 624.01%. Flora Growth has a consensus target price of $6.00, suggesting a potential upside of 358.02%. Given Vincerx Pharma's higher probable upside, equities analysts clearly believe Vincerx Pharma is more favorable than Flora Growth.
Summary
Vincerx Pharma beats Flora Growth on 7 of the 13 factors compared between the two stocks.
Get Vincerx Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VINC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vincerx Pharma Competitors List
Related Companies and Tools
